Dalfampridine prior authorization program: A cohort study

Journal of Managed Care Pharmacy

Volumn 19, Issue 1, 2013, Pages 18-25

  Gleason, Patrick P ^a   Phillips, Jill ^a   Fenrick, Beckie A ^b   Delgado Riley, Ana ^b   Starner, Catherine I ^a  

^a Prime Therapeutics LLC   (United States)

^b Florida Blue   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPYRIDINE;

ADULT; ARTICLE; BLUE CROSS BLUE SHIELD; COHORT ANALYSIS; CONSENSUS DEVELOPMENT; CONTROLLED STUDY; COST UTILITY ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG UTILIZATION; FEMALE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PLANNING; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MULTIPLE SCLEROSIS; PHARMACY; RETROSPECTIVE STUDY; WALKING;

EID: 84874800175     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2013.19.1.18     Document Type: Article

References (18)

1. MacKinnon NJ, Kumar R. Prior authorization programs: a critical review of the literature. J Manag Care Pharm. 2001;7(4):297-302. Available at: http://www.amcp.org/data/jmcp/Review-297-302.pdf.
2. Fallik B. The Academy of Managed Care Pharmacy's concepts in managed care pharmacy: prior authorization and the formulary exception process. Letter to the editor. J Manag Care Pharm. 2005;11(4):358-61. Available at: http://www.amcp.org/data/jmcp/Letters_358-3611.pdf.
3. Carter C, Brookfield R. Consequences of prior authorization programs- a case example: DDAVP in pediatric nocturnal enuresis. Am J Manag Care. 1996;2:715-18.
4. Pharmacy Benefit Management Institute. Prescription drug benefit cost and plan design online report. 2011-2012 edition. Available at: http://www. benefitdesignreport.com/. Accessed December 9, 2012.
5. Academy of Managed Care Pharmacy, Shoemaker SJ, Pozniak A, Subramanian R, Mauch D. Effect of 6 managed care pharmacy tools: a review of the literature. J Manag Care Pharm. 2010;16(6 Suppl):S3-S20. Available at: http://www.amcp.org/data/jmcp/JulSuppA.pdf.
6. Delate T, Mager DE, Sheth J, Motheral BR. Clinical and financial outcomes associated with a proton pump inhibitor prior-authorization program in a Medicaid population. Am J Manag Care. 2005;11(1):29-36.
7. Adams AS, Zhang F, LeCates RF, et al. Prior authorization for antidepressants in Medicaid: effects among disabled dual enrollees. Arch Intern Med. 2009;169(8):750-56. Available at: http://archinte.ama-assn.org/cgi/content/full/169/8/750. Accessed December 9, 2012.
8. Zhang Y, Adams AS, Ross-Degnan D, Zhang F, Soumerai SB. Effects of prior authorization on medication discontinuation among Medicaid beneficiaries with bipolar disorder. Psychiatr Serv. 2009;60(4):520-27.
9. Law MR, Ross-Degnan D, Soumerai SB. Effect of prior authorization of second-generation antipsychotic agents on pharmacy utilization and reimbursements. Psychiatr Serv. 2008;59(5):540-46.
10. McCombs JS, Shi L, Stimmel GL, Croghan TW. A retrospective analysis of the revocation of prior authorization restrictions and the use of antidepressant medications for treating major depressive disorder. Clin Ther. 2002;24(11):1939-59.
11. Fischer MA, Schneeweiss S, Avorn J, Solomon DH. Medicaid priorauthorization programs and the use of cyclooxygenase-2 inhibitors. N Engl J Med. 2004;351(21):2187-94. Available at: http://www.nejm.org/doi/full/10.1056/NEJMsa042770. Accessed December 9, 2012.
12. Gleason PP, Williams C, Hrdy S, Hartwig SC, Lassen D. Medical and pharmacy expenditures after implementation of a cyclooxygenase-2 inhibitor prior authorization program. Pharmacotherapy. 2005;25(7):924-34.
13. Hartung DM, Touchette DR, Ketchum KL, Haxby DG, Goldberg BW. Effects of a prior-authorization policy for celecoxib on medical service and prescription drug use in a managed care Medicaid population. Clin Ther. 2004;26(9):1518-32.
14. Stacy J, Shaw E, Arledge MD, Howell-Smith D. Pharmacoeconomic modeling of prior-authorization intervention for COX-2 specific inhibitors in a 3-tier copay plan. J Manag Care Pharm. 2003;9(4):327-34. Available at: http://www.amcp.org/data/jmcp/Research-327-334.pdf.
15. Ampyra (dalfampridine) prescribing information. Acorda Therapeutics, Inc. 2011. Available at: http://ampyra.com/local/files/Ampyra_PI_ June2012. pdf. Accessed December 9, 2012.
16. U.S. Food and Drug Administration. FDA drug safety communication: seizure risk for multiple sclerosis patients who take Ampyra (dalfampridine). July 23, 2012. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm312846.htm. Accessed December 9, 2012.
17. Miller RM, Happe LE, Meyer KL, Spear RJ. Approaches to the management of agents used for the treatment of multiple sclerosis: consensus statements from a panel of U.S. managed care pharmacists and physicians. J Manag Care Pharm. 2012;18(1):54-62. Available at: http://amcp.org/JMCP/2012/January-February/14484/1033.html.
18. Schafer JA, Gunderson BW, Gleason PP. Price increases and new drugs drive increased expenditures for multiple sclerosis. J Manag Care Pharm. 2010;16(9):713-17. Available at: http://amcp.org/JMCP/2010/November-December/8960/1033.html.